Literature DB >> 9580307

Serum ferritin as a component of the insulin resistance syndrome.

J M Fernández-Real1, W Ricart-Engel, E Arroyo, R Balançá, R Casamitjana-Abella, D Cabrero, M Fernández-Castañer, J Soler.   

Abstract

OBJECTIVE: In epidemiological studies, serum ferritin was the second-strongest determinant of blood glucose (after BMI) in regression models and the third-strongest determinant of serum insulin (after BMI and age). Its concentration also correlated positively with plasma triglycerides and apolipoprotein B concentrations, and negatively with HDL2 cholesterol. We hypothesized that serum ferritin could be a marker of insulin resistance. RESEARCH DESIGN AND METHODS: Oral glucose tolerance and insulin sensitivity (SI, minimal model method) were prospectively evaluated in 36 healthy subjects. The relationship between serum ferritin and metabolic control (as measured by HbA1c levels) was also studied in 76 consecutive NIDDM patients.
RESULTS: In healthy subjects, log-transformed serum ferritin (LOGFER) correlated with basal serum glucose (r = 0.44, P = 0.007), but not with BMI, age, systolic or diastolic blood pressure, total cholesterol, VLDL cholesterol, HDL cholesterol, total triglycerides, VLDL triglycerides, serum insulin, or HbA1c (all P = NS). Identical results were obtained when the two lowest quartiles of serum ferritin were evaluated separately. However, in the two highest quartiles, LOGFER correlated with BMI (0.50, P = 0.02), diastolic blood pressure (r = 0.8, P < 0.0001), serum LDL cholesterol (r = 0.57, P = 0.01), VLDL cholesterol (r = 0.48, P = 0.03), total cholesterol and HDL2 and HDL3 subtractions of HDL cholesterol (r = -0.68, -0.76, -0.55, P = 0.001. < 0.0001, and 0.01, respectively), total triglycerides (r = 0.60, P = 0.006), HDL2/HDL3 quotient (P = -0.71, P = 0.001), VLDL triglycerides (r = 0.65, P = 0.004), and serum uric acid (r = 0.51, P = 0.03), but not with systolic blood pressure (r = 0.38, P = 0.15). After adjusting for BMI, only the correlations between LOGFER and diastolic blood pressure (r = 0.7, P = 0.002) and HDL2/HDL3 quotient (r = -0.63, P = 0.01) remained significant. Strong correlations between LOGFER and glucose area under the curve during oral glucose tolerance test (Pearson's r = 0.73, P = 0.001) and SI (r = -0.68, P = 0.001), which remained significant after controlling for BMI, were observed. LOGFER (beta = -0.44, P = 0.01) and BMI (beta = -0.52, P = 0.004) constituted independent predictors of insulin sensitivity in a multivariate analysis (R2 = 0.68). In 76 consecutive NIDDM outpatients, serum glucose (P < 0.00001) and LOGFER (P = 0.03) independently predicted the value of HbA1c (R2 = 0.40) in a multiple linear regression analysis.
CONCLUSIONS: The correlations among serum ferritin and diastolic blood pressure, HDL quotient, glucose area under the curve, and SI suggest that serum ferritin could be a marker of the insulin resistance syndrome. Serum ferritin may also be an independent determinant of poor metabolic control in the diabetic patient.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9580307     DOI: 10.2337/diacare.21.1.62

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  58 in total

1.  Nonalcoholic fatty liver disease and HFE gene mutations: a Polish study.

Authors:  Joanna Raszeja-Wyszomirska; Grzegorz Kurzawski; Malgorzata Lawniczak; Joanna Miezynska-Kurtycz; Jan Lubinski
Journal:  World J Gastroenterol       Date:  2010-05-28       Impact factor: 5.742

2.  Vascular Accessibility of Endothelial Targeted Ferritin Nanoparticles.

Authors:  Makan Khoshnejad; Vladimir V Shuvaev; Katherine W Pulsipher; Chuanyun Dai; Elizabeth D Hood; Evguenia Arguiri; Melpo Christofidou-Solomidou; Ivan J Dmochowski; Colin F Greineder; Vladimir R Muzykantov
Journal:  Bioconjug Chem       Date:  2016-01-15       Impact factor: 4.774

3.  Dietary iron to total energy intake ratio and type 2 diabetes incidence in a longitudinal 12-year analysis of the Korean Genome and Epidemiology Cohort Study.

Authors:  Dong-Hyuk Jung; Kyeng Won Hong; Byoungjin Park; Yong-Jae Lee
Journal:  Eur J Nutr       Date:  2021-06-03       Impact factor: 5.614

4.  Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial.

Authors:  Shira Zelber-Sagi; Assaf Buch; Hanny Yeshua; Nahum Vaisman; Muriel Webb; Gil Harari; Ofer Kis; Naomi Fliss-Isakov; Elena Izkhakov; Zamir Halpern; Erwin Santo; Ran Oren; Oren Shibolet
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

5.  Nonalcoholic fatty liver disease markers are associated with insulin resistance in type 1 diabetes.

Authors:  Tomislav Bulum; Branko Kolarić; Lea Duvnjak; Marko Duvnjak
Journal:  Dig Dis Sci       Date:  2011-07-07       Impact factor: 3.199

6.  Hypoxia-inducible factor-1alpha regulates beta cell function in mouse and human islets.

Authors:  Kim Cheng; Kenneth Ho; Rebecca Stokes; Christopher Scott; Sue Mei Lau; Wayne J Hawthorne; Philip J O'Connell; Thomas Loudovaris; Thomas W Kay; Rohit N Kulkarni; Terumasa Okada; Xiaohui L Wang; Sun Hee Yim; Yatrik Shah; Shane T Grey; Andrew V Biankin; James G Kench; D Ross Laybutt; Frank J Gonzalez; C Ronald Kahn; Jenny E Gunton
Journal:  J Clin Invest       Date:  2010-05-03       Impact factor: 14.808

7.  Fine-tuned iron availability is essential to achieve optimal adipocyte differentiation and mitochondrial biogenesis.

Authors:  José María Moreno-Navarrete; Francisco Ortega; María Moreno; Wifredo Ricart; José Manuel Fernández-Real
Journal:  Diabetologia       Date:  2014-06-29       Impact factor: 10.122

8.  Role of free radicals in liver diseases.

Authors:  Pablo Muriel
Journal:  Hepatol Int       Date:  2009-11-26       Impact factor: 6.047

9.  Glucose metabolism in the Belgrade rat, a model of iron-loading anemia.

Authors:  Xuming Jia; Jonghan Kim; Tania Veuthey; Chih-Hao Lee; Marianne Wessling-Resnick
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-04-18       Impact factor: 4.052

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.